Flexion Therapeutics (FLXN)
Flexion Therapeutics
NASDAQ:FLXN (11/18/2021, 7:14:27 PM)
After market: 9.121 +0 (+0.01%)9.12
-0.02 (-0.22%)
Company Profile
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. The company is headquartered in Burlington, Massachusetts and currently employs 257 full-time employees. The company went IPO on 2014-02-12. The firm is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. The company is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. The company markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The firm's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.
Company Info
Flexion Therapeutics
10 Mall Rd Ste 301
Burlington MASSACHUSETTS 01803
P: 17813057777.0
CEO: Michael D. Clayman
Employees: 257
Website: https://flexiontherapeutics.com/
FLXN News
NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Echo Global Logistics, Inc. (NASDAQ:ECHO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by The Jordan Company, L.P. for $48.25 per share in cash.If you are an Echo shareholder, click here to learn more
2 years ago - Zacks Investment ResearchPacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss MarkPacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
3 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the Firm/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Atlantic Capital Bancshares, Inc....
3 years ago - WeissLaw LLPSHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
3 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE:...
3 years ago - Zacks Investment ResearchEarnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to DeclineFlexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLXN Twits
Here you can normally see the latest stock twits on FLXN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
